about
Flutamide-induced liver failureHigh arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systemsSoluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertensionSplanchnic and systemic hemodynamic derangement in decompensated cirrhosis.PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertensionCardiac function in patients with early cirrhosis during maximal beta-adrenergic drive: a dobutamine stress study.The insulin like growth factor system in cirrhosis. Relation to changes in body composition following adrenoreceptor blockade.Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver diseaseManagement of cirrhotic ascitesEfficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism.Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.Insulin-like growth factor 1 and growth hormone in chronic liver disease.Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?Hypertension and liver disease.Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.Arterial hypertension and chronic liver disease.Liver cirrhosis and arterial hypertension.Cardiovascular complications of cirrhosis.The heart and the liver.Ascites: pathogenesis and therapeutic principles.Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.Insulin-like growth factor-I and the liver.Indications for portal pressure measurement in chronic liver disease.New insights into cirrhotic cardiomyopathy.Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis.Interactions of the heart and the liver.Cirrhotic cardiomyopathy: pathogenesis and clinical relevance.Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes.Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy.Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature.Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspectsNo difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction.Complications of cirrhosis. A 50 years flashback.The cardiorenal link in advanced cirrhosis.Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis.Outcome of splanchnic blood flow determination in patients with suspected chronic intestinal ischaemia. A retrospective survey.The acid-labile subunit of the ternary insulin-like growth factor complex in cirrhosis: relation to liver dysfunction.
P50
Q28335561-32D5D3B5-2EC0-4223-8893-AC31F4772C23Q28367063-DCE076A3-D7E6-405C-A9FA-5E99AC3EF7F0Q28537987-2530E465-7C3A-4141-98A1-D9EC58A73A84Q34175963-A5CA88CC-A946-4468-9326-C2B14E880D09Q34268818-1343A7DD-FA70-4600-A92B-375BE9D9B07AQ34287422-78F65F4A-F8BD-4B84-B301-C0BFD92EF4E6Q34432154-FFC465E1-BFFB-428D-B404-3A7DE405C987Q34467402-99415C5A-59FC-4129-BF25-3E27CFE14BD2Q34475601-5E0883FA-5ACB-4F9D-A0F8-880CFE3C5565Q34600578-E2272EC3-91F8-438C-99B6-8FD958B5CAFCQ35354293-606D5206-17B7-4964-AE1C-B30ADBE87D20Q35596013-B76A6FBC-FB32-479B-B8DD-F476AB9ACA27Q35814927-4A54632C-C5C5-4199-B135-2E69154E2032Q35873829-438AD800-48DB-4E6E-BDCE-2FDF36FADD2CQ35940029-FF2804A1-B83A-42DF-822A-364B05CDFEC6Q36203618-705DFAC4-BBD9-46FE-8A36-D8741B28E576Q36265537-295D02B2-C152-4BCE-B2C1-D65ACCBC0EE3Q36415436-F926341F-440B-4E54-8916-4366FC74EF3DQ37056007-6AFC296A-EDB8-4CD3-9284-03FE16132798Q37390649-3E611FF2-230D-4D9E-80E5-338C18910DA9Q37500169-2CB8C7C2-695E-4372-AECA-CD4DAD1E9388Q37604322-0EC48FC6-9842-42BF-A964-68CF99F8D7D3Q37898184-6EFB37EE-25A9-476D-A973-CEBDE3CE9F95Q38027225-7C43DEBB-9345-4E69-AA33-9C967B8EE77DQ38049892-E9F8B800-2D71-4E04-BB09-27B61520517FQ38074589-72CF3028-B81C-4CEF-ACA6-5D5C4B46B49FQ38121525-2C45CEF2-6B4E-4C56-B3F5-DC0B6BB431A2Q38161771-A60FA7E8-EDBE-46A8-9772-10C2D0F9237BQ38199770-9E9E8304-67ED-4452-97A4-A58DB80D3C36Q38213559-55D09F05-D31C-4721-9747-98B3B204441AQ38239061-78D00145-1336-44DC-B3F2-0E8E22CD9D79Q38268612-298E241B-18BC-44DA-B03C-12A367F17B92Q38314866-D9A442C7-18DA-449C-80AC-99F84FF4F5BDQ38383495-FDF7E6C6-A4A1-4215-8FE2-495C45FD8A95Q38424360-D713771D-4047-4968-BE5F-899D8EB0C650Q39624441-799D05F9-2FDA-49D8-BE08-30625933D8E2Q40152271-043971ED-A341-4A4D-B7A8-064BC61B7F01Q40536256-5B6AFEDC-2328-4F83-BF23-06631719AA93Q40621052-57CE57C9-A0FA-4BF9-B3A5-7918500D1C5BQ40772066-FD35A256-3A1B-4799-AAD3-06E330AAF135
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Søren Møller
@ast
Søren Møller
@en
Søren Møller
@es
Søren Møller
@nl
Søren Møller
@sl
type
label
Søren Møller
@ast
Søren Møller
@en
Søren Møller
@es
Søren Møller
@nl
Søren Møller
@sl
prefLabel
Søren Møller
@ast
Søren Møller
@en
Søren Møller
@es
Søren Møller
@nl
Søren Møller
@sl
P106
P21
P214
262149294356980522045
P31
P496
0000-0001-9684-7764
P734
P735
P7859
viaf-262149294356980522045